Group 1 - The core viewpoint of the article highlights the significant stock price increase of Pagoda Biopharmaceuticals-B (02565), which rose over 15% and reached a new high of 24.14 HKD during trading [1] - As per Pagoda Biopharmaceuticals-B's prospectus, the drug PB-119, intended for treating Type 2 Diabetes Mellitus (T2DM), is expected to receive NDA approval by 2025 and will be commercialized in China [1] - PB-119 has also initiated Phase Ib/IIa clinical trials for obesity treatment, with participant recruitment expected to be completed by June 2024 [1] Group 2 - The company aims to explore the therapeutic potential of PB-119 in combination therapies, thereby expanding its range of indications beyond T2DM and obesity [1] - The obesity medication market has gained traction, particularly with GLP-1 receptor agonists like semaglutide becoming popular globally [1] - Analysts from CITIC Securities suggest that the obesity medication market is likely to grow rapidly in China, driven by the success of overseas companies like Novo Nordisk and Eli Lilly, as well as accelerated domestic R&D progress [1]
派格生物医药-B午后涨超15%破顶 PB-119用于治疗T2DM预计将于年内获NDA批准